论文部分内容阅读
动脉粥样硬化是一种不能治愈的进行性疾病,常影响冠状动脉灌注。经皮冠状动脉腔内血管成形术(PTCA)自从1977年9月16日首次应用于人体以来,技术上发展迅速,如今已被认为是某些冠心病的选择性治疗方法。技术:在右心室安置临床起搏导管,并给予数种预防血栓的药物(乙酰水杨酸,右旋糖酐和肝素)和血管扩张剂(硝酸酯和钙阻滞剂)以保护病人。经股部或臂部动脉,将一双腔带气囊的导管插到冠状动脉口,置于冠状动脉的狭窄部位,用造影剂充满气
Atherosclerosis is an incurable progressive disease that often affects coronary perfusion. Percutaneous transluminal coronary angioplasty (PTCA) has been rapidly evolving rapidly since it was first applied to the human body on September 16, 1977 and is now considered as a selective treatment for certain forms of coronary heart disease. Technique: A clinical pacing catheter is placed in the right ventricle and several thrombosis-preventing drugs (acetylsalicylic acid, dextran and heparin) and vasodilators (nitrates and calcium blockers) are given to protect the patient. Via the femoral or arm arteries, a double-lumen balloon catheter is inserted into the coronary ostium and placed in the narrow area of the coronary artery, filled with contrast media